S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study

E De Nigris,U Holmgren,J Haughney,C Treharne,A Walker,N Brighton

doi:10.1136/thorax-2021-btsabstracts.110

S104 Cost-effectiveness of triple therapy with budesonide/glycopyrronium/formoterol fumarate versus dual therapies in moderate-to-very severe COPD in the United Kingdom: analysis based on the KRONOS study

E De Nigris, U Holmgren + Show 4 more

Open Access

https://doi.org/10.1136/thorax-2021-btsabstracts.110

Copy DOI

Journal: Thorax	Publication Date: Nov 1, 2021
Citations: 1

Affiliation: AstraZeneca (Sweden), Queen Elizabeth University Hospital, PAREXEL International (United Kingdom)

#Severe Chronic Obstructive Pulmonary Disease #Personal Social Services Research Unit + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

IntroductionThe 24-week KRONOS study (NCT02497001) showed that fixed-dose triple therapy with budesonide/glycopyrronium/formoterol fumarate 320/14.4/10 µg (BGF 320) metered dose inhaler (MDI) was more efficacious at improving lung function than fixed-dose...

Full Text